Bryn Pharma has entered into an agreement with drug delivery specialist Aptar Pharma, for the supply and worldwide exclusive right to use Aptar’s novel, FDA-approved Bidose (BDS) nasal device for the delivery of epinephrine to treat anaphylaxis.   Up to 30 percent of patients who develop anaphylaxis will require a second dose of epinephrine to control symptoms. Current practice parameters recommend that physicians prescribe two epinephrine auto-injectors to be carried by their patients at all ti...